This meta-analysis of randomized controlled trials demonstrates that SGLT2 inhibitors provide consistent and clinically meaningful prognostic benefit across the heart failure spectrum, with strong evidence from large, long-term chronic HF outcome trials and supportive, directionally concordant findings in acute HF settings. The gene discussed is SLC5A2; the disease is hydrops fetalis.